Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains)^[1]. Abatacept is a selective T-cell co-stimulation modulator and a protein drug for the autoimmune diseases^[2].

Abatacept reduces paw edema, and the SC Multiple-dose group shows significantly greater (t_obs = 2.50) paw edema reduction compared with the IV dose group^[2].
Abatacept exhibits linear PK across the studied doses. The NCA clearance (CL) is 20.8 mL/day/kg, volume (V_ss) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%^[2].
Abatacept (oral; 10 mg/kg; every 2 days) reduces the proportion of activated T cells (CD44highCD62L–) and inhibits the up-regulation of ICOS and CD71 in homozygous DO11.10 RAG-2^–/–BALB/c (H-2d/d) mice^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

332348-12-6

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kiykim A, et al. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency. J Allergy Clin Immunol Pract. 2019 Jun 22.

  [2]. Lon HK, et al. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):701-12.

  [3]. Patakas A, et al. Abatacept Inhibition of T Cell Priming in Mice by Induction of a Unique Transcriptional Profile That Reduces Their Ability to Activate Antigen-Presenting Cells. Arthritis Rheumatol. 2016 Mar;68(3):627-38.